Rebiotics Rx

Company Overview

Snapshot

Founded in February 2018, Rebiotics Rx operated with 1–10 employees, focusing on drug development. The company secured one funding round from one investor, Integra Holdings, and holds a patent for its technology. In February 2018, Rebiotics Rx announced a novel computational method for identifying drug candidates for liposomal reformulation, highlighting its early innovation in pharmaceutical development.

Business overview

Rebiotics Rx specializes in repurposing existing FDA-approved antibiotics to combat antibiotic-resistant bacteria. The company's core technology centers on a PEGylated Nanoliposomal-mupirocin formulation, which aims to enhance the systemic activity of mupirocin, an antibiotic effective against critical public health threats like MRSA. By reformulating mupirocin with nanoliposomes, Rebiotics Rx seeks to overcome the drug's short half-life, enabling its parenteral use and effectively creating a novel antibiotic. The company operates within the Pharmaceuticals sector, serving global markets with a B2B2C business model.

Company Intelligence Q&A

What is Rebiotics Rx's primary focus?

Rebiotics Rx focuses on repurposing existing FDA-approved antibiotics to combat antibiotic-resistant bacteria, particularly through its PEGylated Nanoliposomal-mupirocin formulation.

When was Rebiotics Rx founded?

Rebiotics Rx was founded in February 2018.

What is the flagship product of Rebiotics Rx?

The flagship product of Rebiotics Rx is a PEGylated Nanoliposomal-mupirocin formulation, designed to enable parenteral activity of mupirocin against antibiotic-resistant pathogens.

What significant technological development did Rebiotics Rx announce in 2018?

In February 2018, Rebiotics Rx announced a novel computational method for the identification of drug candidates suitable for liposomal reformulation, focusing on nanotechnology and drug delivery.

What is the status of Rebiotics Rx?

Rebiotics Rx is currently non-active and ceased to operate in May 2021.